Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

port any new or continuing symptom to their healthcare provider. BARACLUDE should be taken once daily on an empty stomach (at least two hours after a meal and two hours before the next meal). To learn more about BARACLUDE and for Full Prescribing Information, including boxed WARNINGS, please visit http://www.bms.com/.

Bristol-Myers Squibb is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life. Visit Bristol-Myers Squibb at http://www.bms.com.

BARACLUDE(R) (entecavir) is a trademark of Bristol-Myers Squibb Company.

Full prescribing information for BARACLUDE, including boxed WARNINGS, is available at http://www.bms.com/.

(1) Patients were required to have a screening viral load of greater than

or equal to 10^8 copies/mL at study entry.

(2) In this study, undetectable viral load was defined as HBV DNA less

than 300 copies/mL, measured by PCR assay.


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... West Pharmaceutical Services, Inc. (NYSE: ... has approved payment of the first-quarter 2010 cash dividend ... on February 3, 2010 to shareholders of record on ... ,, West is a global manufacturer of components and ... for vials, and closures and disposable components used in ...
(Date:12/15/2009)... The U.S. Food and Drug Administration (FDA) ... 12 yes, 4 no, and 1 abstention that AstraZeneca ... to support the use of CRESTOR® (rosuvastatin calcium) in ... than or equal to 50 years, women greater than ... < 130 mg/dL; hsCRP greater than or equal to ...
(Date:12/15/2009)... -- SRI International, an independent nonprofit research and ... patent 7,592,021 for a new bioadhesive drug delivery ... the human body,s mucous membranes. This needle-free option ... a much longer release time compared to alternatives ... is an effective means to introduce drugs across ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Scientists identify natural anti cancer defenses 11118 1Scientists identify natural anti cancer defenses 11118 2Smoking Ban Good Step Toward a Healthier Michigan Says Blue Cross 63132 1MassMutual Recognized as One of Americas Healthiest Companies 63127 1MassMutual Recognized as One of Americas Healthiest Companies 63127 2MassMutual Recognized as One of Americas Healthiest Companies 63127 3
(Date:12/15/2009)... About 800,000 doses have lower strength than needed for ... -- Almost 800,000 children,s doses of H1N1 swine flu ... because they have lost some potency, federal health officials ... Disease Control and Prevention, the company,s routine testing of ... 3 years found that four batches had lower than ...
(Date:12/15/2009)... 15 4R Systems, Inc., a leading ... which help retailers significantly increase profits by optimizing ... today that The Vitamin Shoppe has been utilizing ... store and DC inventory solutions have helped us ... in-stocks over the last two years," said Tony ...
(Date:12/15/2009)... Dec. 15 North American application activity ... November year-over-year, according to the MIB Life ... applications over the past three months have lifted ... of -1.6%, to flat at November,s close, -0.1%. ... interest in the benefits available from life insurance," ...
(Date:12/15/2009)... United Nations Foundation has led the fight against malaria, ... Report 2009 that the global strategies for ending malaria deaths are ... the United Nations Foundation , ... Washington, D.C. (Vocus) ... Nations Foundation has led the fight against malaria, and I ...
(Date:12/15/2009)... launches SafeConsole 4.0, the web management software for SafeStick, the ... better usability for employees and more control for administrators through ... , ... Washington, DC (PRWEB) December ... of secure USB devices, today launches SafeConsole 4.0, the web ...
Breaking Medicine News(10 mins):Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3Health News:Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation, on Progress Shown in World Malaria Report 2009 2Health News:BlockMaster Launches SafeConsole 4.0 To Enhance Usability and Security of USB Devices 2Health News:BlockMaster Launches SafeConsole 4.0 To Enhance Usability and Security of USB Devices 3
... WHO:,Dr. Martha J. Farah, Professor of Psychology, ... the Center for Cognitive Neuroscience, University of ... Stress and Brain Development,part of the symposium ... Societal Implications at the 2008 American Association ...
... in situ will not spread, researchers say , , TUESDAY, Feb. ... breast lesion known as ductal carcinoma in situ (DCIS) are ... low risk of a recurrence or of developing invasive breast ... are living as if they,re waiting for the other shoe ...
... , , TUESDAY, Feb. 12 (HealthDay News) -- Americans are spending ... new research suggests those extra dollars aren,t buying more relief. ... of a study in the Feb. 13 issue of the ... lack of results weren,t. , "This calls into question whether ...
... for Top Auction Lot, Benefiting Elton John,s AIDS Foundation ... Feb. 12 It was 80 years ago that ... Leading,Hotels of the World, Ltd. And to celebrate that ... romance and excitement that made the,Academy Award-winning classic "Around ...
... Center in Philadelphia are beginning an 18-month study of ... injecting tiny beads that emit small amounts of radiation ... blood supply feeding the cancers growth. , The technique, ... and Drug Administration for use in inoperable liver cancer. ...
... Scholarship Applications for the 2008-2009 Academic Year Are ... Association,of Colleges of Nursing (AACN) and the Johnson ... announce that the first five Minority Nurse,Faculty Scholars ... address the,nation,s shortage of nurse educators. This program ...
Other Medicine News:Health News:Precancerous Breast Lesions Cause Unnecessary Worry 2Health News:Precancerous Breast Lesions Cause Unnecessary Worry 3Health News:Precancerous Breast Lesions Cause Unnecessary Worry 4Health News: Back Pain Spending Up, Relief Down 2Health News: Back Pain Spending Up, Relief Down 3Health News:The Leading Hotels of the World Recreates Film Fantasy in Uber-Luxury Trip: Around The World in 80 Ways 2Health News:The Leading Hotels of the World Recreates Film Fantasy in Uber-Luxury Trip: Around The World in 80 Ways 3Health News:The Leading Hotels of the World Recreates Film Fantasy in Uber-Luxury Trip: Around The World in 80 Ways 4Health News:The Leading Hotels of the World Recreates Film Fantasy in Uber-Luxury Trip: Around The World in 80 Ways 5Health News:New Jefferson trial to test radiation-emitting beads against advanced liver cancer 2Health News:First Group of Minority Nurse Faculty Scholars Selected by the Johnson & Johnson Campaign for Nursing's Future and AACN 2Health News:First Group of Minority Nurse Faculty Scholars Selected by the Johnson & Johnson Campaign for Nursing's Future and AACN 3
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... serum. Antibodies to Sm aid ... lupus erythematosus (SLE). ,RNP antibodies ...
... ENA Screen ELISA test system is a ... to extractable nuclear antigens (anti-ENA) in human ... insert, this test system is capable of ... as those against Jo-1, Sm, Sm/RNP, SSA, ...
... The RELISA ENA assays were designed with ... the clinician in the diagnosis of autoimmune ... rheumatic disease and 1,000 normal individuals were ... ENA Test System. Immuno Concepts compared the ...
Inquire...
Medicine Products: